Clinical Trial Update: A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of subcutaneous LIPO-102 versus placebo for reducing abdominal subcutaneous adiposity; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• LIPO-102

Snippet

Sponsor: Neothetics, Inc | Conditions: Weight | Phase 2 | Status: COMPLETED